From: Catastrophic pharmaceutical expenditure in patients with type 2 diabetes in Iran
Scenario | Treatment schedule | Rural (2%) | Rural (8%) | Urban (2%) | Urban (8%) |
---|---|---|---|---|---|
Monotherapy | Metformin | 0% | 0% | 0% | 0% |
Glibenclamide | 0% | 0% | 0% | 0% | |
Gliclazide | 0% | 0% | 0% | 0% | |
Dual therapy | Metformin + Acarbose | 0% | 0% | 0% | 0% |
Metformin + Repaglinide | 4% | 4% | 0% | 0% | |
Metformin + Glibenclamide | 0% | 0% | 0% | 0% | |
Metformin + Gliclazide | 0% | 0% | 0% | 0% | |
Metformin + Pioglitazone | 4% | 0% | 0% | 0% | |
Triple oral therapy | Metformin + Pioglitazone + Glibenclamde | 4% | 4% | 0% | 0% |
Metformin + Pioglitazone + Gliclazide | 4% | 4% | 0% | 0% | |
Metformin + Pioglitazone + Acarbose | 4% | 4% | 0% | 0% | |
Oral therapy + Insulin | Metformin + Insulin isophane | 4% | 4% | 4% | 0% |
Metformin + Insulin glargine | 46% | 12% | 22% | 4% | |
Metformin + Insulin detemir | 94% | 56% | 90% | 31% |